At PLUS THERAPEUTICS, we fully understand that establishing successful relationships with global business partners and suppliers are essential to fulfilling our company mission in discovering, developing, and delivering complex and innovative treatments for patients battling cancer and other life-threatening diseases.  

We aim to collaborate with parties that share similar priorities and values and can benefit from PLUS THERAPEUTICS’ strengths — proprietary technology, deep product and clinical development expertise, and in-house manufacturing and analytical testing capabilities.  We are also seeking collaborations with parties that can help PLUS THERAPEUTICS continue to innovate, advance and expand our product pipeline, and deliver new treatments to patients in need around the globe.  

We believe that we can create more value for and establish a higher bar in the healthcare industry by working together.


PEGylated Liposomes

PLUS THERAPEUTICS’ approach to drug delivery with PEGylated liposomes is both proprietary and versatile, offering potential partners a nanotechnology platform with which to reformulate a wide range of hydrophilic and lipophilic Active Pharmaceutical Ingredients, or APIs, for a multitude of new clinical applications.  Partnering with PLUS THERAPEUTICS may represent a means to expand commercial opportunities while reducing cost and time associated with development activities.  

To learn more about our PEGylated liposomes, please contact us at


PLUS THERAPEUTICS’ is constantly striving to find novel ways to broaden and fortify the applicability and relevance of our nanotechnology platform.  We are open to exploring how to enhance our PEGylated liposomes to carry and locally deliver one or more drugs:

+ in a safer and more effective manner

+ via new routes of administration, and

+ for new clinical indications with significant unmet needs.

Do you have an idea on how we can accomplish this goal?  If so, please contact us at


Patented DocePLUS™

DocePLUS™ is an albumin-stabilized PEGylated liposomal docetaxel that is being developed as a new therapy for Small Cell Lung Cancer and potential replacement for HYCAMTIN® (topotecan), the only U.S. FDA-approved second-line therapy.  According to the World Health Organization, in 2015 over 1.1 billion people smoked tobacco.  Given that tobacco smoking is by far the leading cause of Small Cell Lung Cancer and that treatment regimens have changed little since HYCAMTIN® was approved 20 years ago, we believe there is potentially a significant global market opportunity for DocePLUS™.  We are actively seeking development and commercial partners for this Phase 2-ready asset for all markets, with a priority on the United States, Europe, and China.

Further, based on results from 1) comprehensive, independent, primary market research performed with U.S. medical oncologists and payers and 2) the completed U.S. Phase 1 clinical trial, we believe there is also a compelling market opportunity for DocePLUS® as a therapy for other solid tumors, including Pancreatic Cancer, Breast Cancer, Esophageal Cancer, and Cholangiocarcinoma.  The combined annual revenue potential for DocePLUS™ for these clinical indications is estimated at over $600M.  

Please contact us at if interested in DocePLUS™ for Small Cell Lung Cancer or other clinical applications.

HYCAMTIN is a registered trademark of Novartis Pharmaceuticals Corporation.

Generic DoxoPLUS™

The European market for PEGylated liposomal doxorubicin is estimated at $120M+ annually and is held entirely today by the originator-reference drug, CAELYX®.  With DoxoPLUS™, we are looking to offer healthcare providers and their patients a lower-cost generic alternative to CAELYX® for the treatment of breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s sarcoma.  We anticipate that DoxoPLUS™ will launch in Europe in 2021 and are actively seeking a commercial partner with a strong track record with generic oncology injectables.  

Outside of Europe, we believe there is an opportunity to leverage our DoxoPLUS™ nonclinical and bioequivalence clinical trial data to accelerate the path to gain authorization in China and elsewhere where CAELYX® is the originator-reference drug.  Our manufacturing facility and team in San Antonio, Texas has the potential capacity and experience to supply global markets with a high-quality DoxoPLUS™ product.  

Please contact us at if interested in DoxoPLUS™ for Europe or other major markets.

CAELYX is a registered trademark of Janssen Products, LP.


PLUS THERAPEUTICS is continually evaluating the most efficient and effective way to get things done.  In many cases, we have the right people, materials, equipment, and facilities in-house to complete a particular task, project, or process.  In other cases, outsourcing and partnering is a preferred alternative.  

We are looking for new suppliers and vendors to help us in the areas of raw materials, product and clinical development, analytical chemistry, manufacturing, quality, regulatory affairs, and industry partnerships.  If interested, please contact us at